NO20060022L - Stabile sammensetninger av atorvastatin fremstilt ved vat granulering - Google Patents
Stabile sammensetninger av atorvastatin fremstilt ved vat granuleringInfo
- Publication number
- NO20060022L NO20060022L NO20060022A NO20060022A NO20060022L NO 20060022 L NO20060022 L NO 20060022L NO 20060022 A NO20060022 A NO 20060022A NO 20060022 A NO20060022 A NO 20060022A NO 20060022 L NO20060022 L NO 20060022L
- Authority
- NO
- Norway
- Prior art keywords
- atorvastatin
- granulation
- cotton
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
Abstract
Våtgranulert, farmasøytisk sammensetning omfattende atorvastatin eller et farmasøytisk akseptabelt salt derav med mindre enn ca. 5 vektprosent av et alkalisk jordmetallsaltadditiv med en desintegrant som tilveiebringer atorvastatinet med ikke mer enn ca. 3 % atorvastatinlakton, basert på forholdet mellom laktontoppareal versus de samlete medikamentielaterte toppintegrerte arealer, så vel som den toppgranulerte, farmasøytiske sammensetning, omfattende atorvastatin eller et farmasøytisk akseptabelt salt derav i kombinasjon med minst ett annet virkestoff, fremgangsmåter for å fremstille nevnte sammensetninger, utstyr for å romme slike sammensetninger, og en fremgangsmåte for å behandle hyperkolesterolemi og/eller hyperlipidemi, osteoporose, godartet prostatisk hyperplasi (BPH), og Alzheimers sykdom ved anvendelse av en terapeutisk effektiv mengde av de farmasøytiske sammensetninger.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47811903P | 2003-06-12 | 2003-06-12 | |
PCT/IB2004/001862 WO2004110431A1 (en) | 2003-06-12 | 2004-06-01 | Stable compositions of atorvastatin prepared with wet granulation |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060022L true NO20060022L (no) | 2006-01-03 |
Family
ID=33551806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060022A NO20060022L (no) | 2003-06-12 | 2006-01-03 | Stabile sammensetninger av atorvastatin fremstilt ved vat granulering |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1635814A1 (no) |
JP (1) | JP2006527260A (no) |
KR (1) | KR100814218B1 (no) |
CN (1) | CN100434069C (no) |
AR (1) | AR044774A1 (no) |
AU (1) | AU2004246868B2 (no) |
BR (1) | BRPI0411344A (no) |
CA (1) | CA2465565A1 (no) |
CO (1) | CO5650230A2 (no) |
MX (1) | MXPA05013281A (no) |
NO (1) | NO20060022L (no) |
NZ (1) | NZ543337A (no) |
RU (1) | RU2332211C2 (no) |
TW (1) | TW200503690A (no) |
WO (1) | WO2004110431A1 (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
EP2170294A1 (en) * | 2007-06-25 | 2010-04-07 | Pharmathen S.A. | Improved pharmaceutical formulation containing an hmg-coa reductase inhibitor and method for the preparation thereof |
CN102089016A (zh) * | 2008-02-27 | 2011-06-08 | 托门医学股份公司 | 植入物及其制备方法 |
AU2009292615B2 (en) * | 2008-09-17 | 2015-12-03 | Mylan Inc. | Granulates, process for preparing them and pharmaceutical products containing them |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
WO2013072770A2 (en) | 2011-11-15 | 2013-05-23 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
CN104069078B (zh) * | 2014-05-22 | 2019-06-11 | 西藏九瑞健康股份有限公司 | 阿托伐他汀钙药物组合物及其制备方法 |
SG10201900648SA (en) * | 2014-07-25 | 2019-02-27 | Novartis Ag | Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide |
KR101658350B1 (ko) * | 2015-02-06 | 2016-09-30 | 경성대학교 산학협력단 | 고지혈증 치료에 유용한 약학 조성물 |
EP3267977B1 (en) * | 2015-03-12 | 2021-08-11 | DuPont Nutrition USA, Inc. | Solid dispersions |
JPWO2017170858A1 (ja) | 2016-03-31 | 2019-02-14 | インターセプト ファーマシューティカルズ, インコーポレイテッド | 溶出性に優れた経口製剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994016693A1 (en) * | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
JPH06242003A (ja) * | 1993-02-12 | 1994-09-02 | Nkk Corp | 鉄鋼中のアルミナの粒度測定方法 |
JP3014040B2 (ja) * | 1996-10-30 | 2000-02-28 | 信久 川野 | 食物繊維パン及びその製造法 |
EP2382970B1 (en) * | 2000-04-10 | 2013-01-09 | Teva Pharmaceutical Industries, Ltd. | Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids or 7-Substituted-3,5-Dihydroxyheptenoic Acids |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
EP1226818A1 (en) * | 2001-01-26 | 2002-07-31 | Pfizer Products Inc. | Pharmaceutical dosage forms with enhanced cohesive and compressibility properties |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
-
2004
- 2004-04-29 CA CA002465565A patent/CA2465565A1/en not_active Abandoned
- 2004-06-01 JP JP2006516512A patent/JP2006527260A/ja active Pending
- 2004-06-01 BR BRPI0411344-6A patent/BRPI0411344A/pt not_active IP Right Cessation
- 2004-06-01 KR KR1020057023669A patent/KR100814218B1/ko not_active IP Right Cessation
- 2004-06-01 NZ NZ543337A patent/NZ543337A/en unknown
- 2004-06-01 EP EP04735614A patent/EP1635814A1/en not_active Withdrawn
- 2004-06-01 RU RU2005136745/15A patent/RU2332211C2/ru not_active IP Right Cessation
- 2004-06-01 AU AU2004246868A patent/AU2004246868B2/en not_active Ceased
- 2004-06-01 MX MXPA05013281A patent/MXPA05013281A/es not_active Application Discontinuation
- 2004-06-01 CN CNB2004800163910A patent/CN100434069C/zh not_active Expired - Fee Related
- 2004-06-01 WO PCT/IB2004/001862 patent/WO2004110431A1/en active Application Filing
- 2004-06-10 AR ARP040102008A patent/AR044774A1/es unknown
- 2004-06-11 TW TW093116894A patent/TW200503690A/zh unknown
-
2005
- 2005-12-09 CO CO05124741A patent/CO5650230A2/es not_active Application Discontinuation
-
2006
- 2006-01-03 NO NO20060022A patent/NO20060022L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1805741A (zh) | 2006-07-19 |
CO5650230A2 (es) | 2006-06-30 |
CN100434069C (zh) | 2008-11-19 |
NZ543337A (en) | 2008-03-28 |
AR044774A1 (es) | 2005-10-05 |
RU2005136745A (ru) | 2006-07-27 |
AU2004246868B2 (en) | 2008-01-17 |
RU2332211C2 (ru) | 2008-08-27 |
TW200503690A (en) | 2005-02-01 |
EP1635814A1 (en) | 2006-03-22 |
BRPI0411344A (pt) | 2006-07-11 |
AU2004246868A1 (en) | 2004-12-23 |
KR100814218B1 (ko) | 2008-03-17 |
MXPA05013281A (es) | 2006-03-09 |
CA2465565A1 (en) | 2004-12-12 |
WO2004110431A1 (en) | 2004-12-23 |
KR20060020666A (ko) | 2006-03-06 |
JP2006527260A (ja) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060022L (no) | Stabile sammensetninger av atorvastatin fremstilt ved vat granulering | |
NO20060149L (no) | Farmasoytiske forbindelser av atorvastatin | |
NO20055185L (no) | Farmasoytiske sammensetninger omfattende atorvastatin fremstilt uten granulering | |
NO952863D0 (no) | Fluoxetin-farmasöytiske sammensetninger | |
BE2015C026I2 (en) | 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens | |
EA200001125A1 (ru) | Гелеобразные фармацевтические композиции | |
AU2721402A (en) | Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto | |
NO20061640L (no) | Hurtig opplosningspreparat av en kalsiumreseptiraktiv forbindelse | |
LU92166I2 (fr) | Glycopyrronium ou un de ses sels | |
NO20064670L (no) | Galeniske formuleringer av organiske forbindelser | |
YU96602A (sh) | Postupak za spravljanje smeše | |
MA27809A1 (fr) | Amides d'acide pyrrolopyridine-2-carboxylique inhibiteurs de glycogene-phosphorylase | |
WO2006118948A3 (en) | Therapeutic compositions | |
MY138023A (en) | Compositions and process for preparing cleansing bars comprising low levels of soluble surfactant for enhanced fragrance deposition/longevity | |
EA200200132A1 (ru) | СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ | |
ME00706B (me) | Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze | |
CA2378834A1 (en) | Pyrazinones, compositions containing such compounds | |
DE60018545D1 (de) | Zusammensetzung zur Behandlung von degenerativen Gelenkerkrankungen | |
JO2231B1 (en) | Derivatives of Trahydroperan and its use as a therapeutic agent | |
EA200100871A1 (ru) | Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения | |
TNSN03065A1 (en) | BIOPESTICIDE COMPOSITIONS | |
WO2001066119A3 (en) | Pharmaceutical compositions including alginates | |
ATE535242T1 (de) | Medizinische zusammensetzung zur prävention des übergangs zu einer operativen behandlung bei prostatahypertrophie | |
WO2002053099A3 (en) | Methods and compositions for treating periodontal disease | |
WO2007023281A3 (en) | Biologically active compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |